Sernova Biotherapeutics (TSV:SVA)

N/A UNCHANGED

Last Price Updated: 3:59 PM EDT, Jun 1, 2022 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	1.550 (51)
Ask (Size)	1.610 (5)
Prev. Close	1.570
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late? ↗

May 26, 2022

Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited...

Via Benzinga

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act

May 06, 2022

From Sinovac Biotech Ltd.

Via Business Wire

Performance

More News

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F

April 29, 2022

From Sinovac Biotech Ltd.

Via Business Wire

Sinovac Amends Shareholder Rights Plan

February 22, 2022

From Sinovac Biotech Ltd.

Via Business Wire

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

Via InvestorPlace

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report ↗

January 26, 2022

Via Benzinga

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows ↗

January 24, 2022

Via Benzinga

Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters ↗

January 03, 2022

Via Benzinga

SINOVAC Reports Unaudited First Half of 2021 Financial Results

December 30, 2021

From Sinovac Biotech Ltd.

Via Business Wire

Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment

December 09, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

SINOVAC Beijing Settled Litigation of Its Business License and Seals

December 03, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population

November 09, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters ↗

September 24, 2021

Via Benzinga

Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion ↗

September 11, 2021

Via Talk Markets

New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant

September 09, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents

September 08, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Via Benzinga

Inovio To Start Global Late-Stage COVID-19 Vaccine Trial ↗

August 26, 2021

Via Benzinga

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations

August 10, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine ↗

July 20, 2021

Via Benzinga

SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy

July 19, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot ↗

July 16, 2021

Via Benzinga

SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX

July 12, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old

June 30, 2021

From Sinovac Biotech Ltd.

Via Business Wire

World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use

June 02, 2021

From SINOVAC Biotech Ltd.

Via Business Wire

Frequently Asked Questions

Is Sernova Biotherapeutics publicly traded?

Yes, Sernova Biotherapeutics is publicly traded.

What exchange does Sernova Biotherapeutics trade on?

Sernova Biotherapeutics trades on the Toronto Venture Stock Exchange

What is the ticker symbol for Sernova Biotherapeutics?

The ticker symbol for Sernova Biotherapeutics is SVA on the Toronto Venture Stock Exchange